Experience of continuous subcutaneous insulin infusion in the outpatient management of diabetic teenagers.
Of forty-five adolescent diabetic patients offered continuous subcutaneous insulin infusion (CSII) as part of a large feasibility study, 13 (28.9%) initially chose the treatment, but only 4 out of 11 who actually started CSII continued for one year (64% discontinuation rate). In contrast 30.4% of adults approached chose CSII, and 32% had discontinued after one year. Improvement in glycaemic control was poor, and clinical problems were more common in pump-treated teenagers than in adults. CSII does not appear to be a therapeutic solution for adolescents having difficult management problems.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D007332:Insulin Infusion Systems; D008297:Male; D010045:Outpatients; D010349:Patient Compliance
D001786:Blood Glucose; D007328:Insulin